MedTrace Logo

Biobanking Upper Gastrointestinal Tumors to Evaluate Response (BURGER With BACON)

NCT06283238 · Status: WITHDRAWN · Type: OBSERVATIONAL

Last updated 2026-01-29

No results posted yet for this study

Summary

The goal of this observational study is to examine genetic changes that may contribute to immunotherapy resistance in gastroesophageal cancer. This information can potentially lead to the identification of new immunotherapeutic targets as well as improve the ability to identify those patients more likely to respond to immunotherapy.

This study does not include any treatment or investigational drugs.

Participants will be asked:

* to enroll before beginning standard care of treatment for their cancer
* for blood, archived tumor tissue, and fresh tumor tissue Researchers will compare participants who are not getting immunotherapy to identify potential differences in expression levels of a gene.

Conditions

Interventions

DRUG

Immune checkpoint inhibitor (ICI) or chemotherapy alone

Immune checkpoint inhibitor (i.e. pembrolizumab, nivolumab, or another checkpoint inhibitor) or chemotherapy alone

Sponsors & Collaborators

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-04-16
Primary Completion
2026-03-25
Completion
2027-03-25
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06283238 on ClinicalTrials.gov